Abstract 318P
Background
EMPOWER-Lung 3 is a randomised, 2-part, Phase 3 study of 1L treatment of patients (pts) with advanced (Stage III/IV) squamous (SQ) or non-squamous (NSQ) NSCLC without actionable mutations (NCT03409614). The double-blind Part 2 of the study enrolled pts irrespective of PD-L1 levels and compared clinical activity and safety of cemiplimab, an anti-PD-1, plus (+) platinum-based chemo, versus (vs) placebo (PBO)+chemo.
Methods
Pts were randomised (2:1; stratified by histology and PD-L1 expression) to receive cemiplimab 350 mg once every 3 weeks (Q3W) or PBO Q3W for 108 weeks (or until progression), plus up to 4 cycles of chemo (followed by mandatory pemetrexed maintenance for NSQ pts assigned to a pemetrexed-containing regimen). Primary endpoint was overall survival (OS). Key secondary endpoints include progression-free survival (PFS) and objective response rate (ORR) per blinded independent central review. Here we report Part 2 results from the prespecified 2 interim analysis. Data cut-off was 14 June 2021.
Results
Overall, 466 pts were eligible and randomised to cemiplimab+chemo (n=312) or PBO+chemo (n=154). Median (range) age was 63.0 (25-84) years; 57.1% had NSQ NSCLC; and 85.2% had Stage IV disease. Median OS was 21.9 months with cemiplimab+chemo vs 13.0 months with PBO+chemo (HR, 0.71; P=0.014). Cemiplimab+chemo was associated with superior median PFS (8.2 vs 5.0 months; HR, 0.56), higher ORR (43.3% vs 22.7%), and longer median duration of response (DOR) (15.6 months vs 7.3 months) vs PBO+chemo (Table). Incidence of Grade ≥3 adverse events was 43.6% in cemiplimab+chemo arm and 31.4% in PBO+chemo arm. Table: 318P
Cemiplimab+chemo (n=312) | PBO+chemo (n=154) | ||
Duration of follow-up, median (IQR), months | 16.3 (13.9–19.1) | 16.7 (14.2–19.0) | |
OS, median (95% CI), months | 21.9 (15.5–NE) | 13.0 (11.9–16.1) | |
HR (95% CI) | 0.71 (0.53–0.93); P=0.014 | ||
PFS, median (95% CI), months | 8.2 (6.4–9.3) | 5.0 (4.3–6.2) | |
HR (95% CI) | 0.56 (0.44–0.70); P<0.0001 | ||
ORR, % (95% CI) | 43.3 (37.7–49.0) | 22.7 (16.4–30.2) | |
Odds ratio (95% CI) | 2.68 (1.72–4.19); P<0.0001 | ||
Complete response, n (%) | 8 (2.6) | 0 (0) | |
Partial response, n (%) | 127 (40.7) | 35 (22.7) | |
Kaplan-Meier estimated DOR, median (95% CI), months | 15.6 (12.4–NE) | 7.3 (4.3–12.6) |
Conclusions
In pts with advanced NSCLC, 1L cemiplimab+chemo demonstrated clinically meaningful and statistically significant improvement in OS, PFS, ORR and DOR vs chemo alone, with a safety profile consistent with cemiplimab monotherapy and platinum-based chemo.
Clinical trial identification
NCT03409614.
Editorial acknowledgement
Medical writing support was provided by Jenna Lee, MS of Prime, Knutsford, UK, funded by Regeneron Pharmaceuticals, Inc., and Sanofi. Responsibility for all opinions, conclusions, and data interpretation lies with the authors.
Legal entity responsible for the study
Regeneron Pharmaceuticals, Inc., and Sanofi.
Funding
Regeneron Pharmaceuticals, Inc., and Sanofi.
Disclosure
K.D. Penkov: Financial Interests, Personal, Advisory Role: AstraZeneca, Merck Sharp & Dohme, Nektar, Pfizer, Regeneron Pharmaceuticals, Inc., and Roche. E. Kalinka: Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Nektar, Pfizer, Roche, and Regeneron Pharmaceuticals, Inc. C. Gessner: Financial Interests, Personal, Advisory Board: AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi. R. Passalacqua: Financial Interests, Personal, Advisory Board: Astellas, Bristol Myers Squibb, Ipsen, Janssen, Merck Sharp & Dohme, Roche, and Sanofi-Aventis; Financial Interests, Institutional, Research Grant: Amgen, AstraZeneca, Novartis, and Pierre-Fabre. S. Li, K. McGuire, R.G. Quek, G. Gullo, P. Rietschel: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
334P - Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Geographic region subgroups in EMPOWER-Lung 1
Presenter: Gwo Fuang Ho
Session: Poster viewing 05.
335P - Real-world data of first-line treatment with pembrolizumab for non-small cell lung cancer with high PD-L1 expression (HOT/NJLCG2001)
Presenter: Hiroshi Yokouchi
Session: Poster viewing 05.
336P - Spatial characterisation of immune microenvironment in malignant pleural mesothelioma
Presenter: Dmitrii Shek
Session: Poster viewing 05.
337P - Association of clinical and molecular factors with immune checkpoint inhibitors efficacy in advanced non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Feng Li
Session: Poster viewing 05.
338P - Anti PD1 is superior to anti PDL1 when combined with chemotherapy in first-line treatment for metastatic non-small cell lung cancer (mNSCLC): A network meta-analysis
Presenter: Joe Wei
Session: Poster viewing 05.
339P - Analysis of first- and second-line immunotherapy efficacy in metastatic non-small cell lung cancer with low PD-L1 expression
Presenter: Charlotte McKay
Session: Poster viewing 05.
341P - Cost-effectiveness analysis of first-line atezolizumab for patients with stage IV non-small cell lung cancer whose tumours have a high-programmed death ligand 1 expression in Thailand
Presenter: Kankamon Kittrongsiri
Session: Poster viewing 05.
342P - Prognostic implications of PD-L1 co-expression among Filipino EGFR MT mNSCLC
Presenter: Herdee Gloriane Luna
Session: Poster viewing 05.
343P - Immunotherapy as first-line treatment in metastatic non-small cell lung cancer: A single center experience
Presenter: Harshitha N.J
Session: Poster viewing 05.